In summary, CD8+CD28− and CD8+PD1+ T cells are linked to high-risk clinical features in EC, while tumor-infiltrating CD8+CD28+PD1− T cells serve as a key independent prognostic marker for relapse. The gene discussed is CD8A; the disease is neoplasm.